By Feroz Jameel, Susan Hershenson
ISBN-10: 0470118121
ISBN-13: 9780470118122
ISBN-10: 0470595884
ISBN-13: 9780470595886
A real-world advisor to the creation and production of biopharmaceuticals
While a lot has been written in regards to the technology of biopharmaceuticals, there's a desire for functional, updated info on key concerns in any respect phases of constructing and production commercially plausible biopharmaceutical drug items. This ebook is helping fill the space within the box, interpreting all components of biopharmaceuticals production, from improvement and formula to construction and packaging.
Written through a gaggle of specialists from and academia, the e-book makes a speciality of real-world tools for conserving product integrity through the commercialization strategy, in actual fact explaining the basics and crucial pathways for all improvement phases. insurance comprises:
-
Research and early improvement phase?appropriate ways for making sure product stability
-
Development of commercially potential formulations for liquid and lyophilized dosage forms
-
Optimal garage, packaging, and transport methods
-
Case reports with regards to healing monoclonal antibodies, recombinant proteins, and plasma fractions
-
Useful research of profitable and failed products
Formulation and strategy improvement thoughts for production Biopharma-ceuticals is a necessary source for scientists and engineers within the pharmaceutical and biotech industries, for presidency and regulatory organisations, and for an individual with an curiosity within the most modern advancements within the field.Content:
Chapter 1 The constitution of organic Therapeutics (pages 1–40): Sheryl Martin?Moe, Tim Osslund, Y. John Wang, Tahir Mahmood, Rohini Deshpande and Susan Hershenson
Chapter 2 Chemical Instability in Peptide and Protein prescribed drugs (pages 41–67): Elizabeth M. Topp, Lei Zhang, Hong Zhao, Robert W. Payne, Gabriel J. Evans and Mark Cornell Manning
Chapter three actual balance of Protein prescribed drugs (pages 69–104): Byeong S. Chang and Bernice Yeung
Chapter four Immunogenicity of healing Proteins (pages 105–117): Steven J. Swanson
Chapter five Preformulation learn: Assessing Protein resolution habit in the course of Early improvement (pages 119–146): Bernardo Perez?Ramirez, Nicholas Guziewicz and Robert Simler
Chapter 6 formula improvement of section 1–2 Biopharmaceuticals: an effective and well timed technique (pages 147–159): Nicholas W. Warne
Chapter 7 Late?Stage formula improvement and Characterization of Biopharmaceuticals (pages 161–171): Adeola O. Grillo
Chapter eight An Empirical section Diagram–High?Throughput Screening method of the Characterization and formula of Biopharmaceuticals (pages 173–205): Sangeeta B. Joshi, Akhilesh Bhambhani, Yuhong Zeng and C. Russell Middaugh
Chapter nine Fluorescence and Phosphorescence ways to Probe Protein constitution and balance in Ice: The Case of Azurin (pages 207–229): Giovanni B. Strambini
Chapter 10 functions of Sedimentation speed Analytical Ultracentrifugation (pages 231–251): Tom Laue
Chapter eleven box movement Fractionation with Multiangle gentle Scattering for Measuring Particle measurement Distributions of Virus?Like debris (pages 253–268): Joyce A. Sweeney and Christopher Hamm
Chapter 12 Light?Scattering strategies and their software to formula and Aggregation issues (pages 269–305): Michael Larkin and Philip Wyatt
Chapter thirteen potent techniques to formula improvement of Biopharmaceuticals (pages 307–328): Rajiv Nayar and Mitra Mosharraf
Chapter 14 Prediction of Aggregation Propensity from basic series info (pages 329–347): Mark Cornell Manning, Gabriel J. Evans, Cody M. Van Pelt and Robert W. Payne
Chapter 15 High?Concentration Antibody Formulations (pages 349–381): Steven J. Shire, Jun Liu, Wolfgang Friess, Susanne Jorg and Hanns?Christian Mahler
Chapter sixteen improvement of Formulations for healing Monoclonal Antibodies and Fc Fusion Proteins (pages 383–427): Sampathkumar Krishnan, Monica M. Pallitto and Margaret S. Ricci
Chapter 17 Reversible Self?Association of Pharmaceutical Proteins: Characterization and Case reviews (pages 429–455): Vikas okay. Sharma, Harminder Bajaj and Devendra S. Kalonia
Chapter 18 layout of a formula for Freeze Drying (pages 457–492): Feroz Jameel and Mike J. Pikal
Chapter 19 Protein Conformation and Reactivity in Amorphous Solids (pages 493–506): Lei Zhang, Sandipan Sinha and Elizabeth M. Topp
Chapter 20 The effect of Buffer on Solid?State homes and balance of Freeze?Dried Dosage kinds (pages 507–519): Evgenyi Y. Shalaev and Larry A. Gatlin
Chapter 21 Stabilization of Lyophilized prescription drugs through keep watch over of Molecular Mobility: impression of Thermal historical past (pages 521–548): Suman Luthra and Michael J. Pikal
Chapter 22 Structural research of Proteins in Dried Matrices (pages 549–563): Andrea Hawe, Sandipan Sinha, Wolfgang Friess and Wim Jiskoot
Chapter 23 The effect of formula and Drying techniques at the features and function of Biopharmaceutical Powders (pages 565–585): Vu L. Truong and Ahmad M. Abdul?Fattah
Chapter 24 production basics for Biopharmaceuticals (pages 587–604): Maninder Hora
Chapter 25 Protein balance in the course of Bioprocessing (pages 605–624): Mark Cornell Manning, Gabriel J. Evans and Robert W. Payne
Chapter 26 Freezing and Thawing of Protein strategies (pages 625–675): Satish okay. Singh and Sandeep Nema
Chapter 27 techniques for Bulk garage and cargo of Proteins (pages 677–704): Feroz Jameel, Chakradhar Padala and Theodore W. Randolph
Chapter 28 Drying procedure equipment for Biopharmaceutical items: an summary (pages 705–738): Ahmad M. Abdul?Fattah and Vu L. Truong
Chapter 29 Spray Drying of Biopharmaceuticals and Vaccines (pages 739–761): Jim Searles and Govindan Mohan
Chapter 30 improvement and Optimization of the Freeze?Drying procedures (pages 763–796): Feroz Jameel and Jim Searles
Chapter 31 issues for winning Lyophilization method Scale?Up, know-how move, and regimen creation (pages 797–826): Samir U. Sane and Chung C. Hsu
Chapter 32 method Robustness in Freeze Drying of Biopharmaceuticals (pages 827–837): D. Q. Wang, D. MacLean and X. Ma
Chapter 33 Filling strategies and applied sciences for Liquid Biopharmaceuticals (pages 839–856): Ananth Sethuraman, Xiaogang Pan, Bhavya Mehta and Vinay Radhakrishnan
Chapter 34 Leachables and Extractables (pages 857–880): Jim Castner, Pedro Benites and Michael Bresnick
Chapter 35 fundamental box and Closure choice for Biopharmaceuticals (pages 881–896): Olivia Henderson
Chapter 36 Prefilled Syringes for Biopharmaceuticals (pages 897–916): Robert Swift
Chapter 37 influence of producing procedures on Drug Product balance and caliber (pages 917–940): Nitin Rathore, Rahul S. Rajan and Erwin Freund
Read or Download Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals PDF
Similar manufacturing books
Implementing and Configuring SAP MII
Enforce and configure SAP MII to suit your various production initiatives and matters with this must-have, finished advisor to SAP MII. methods to create composite purposes that attach your enterprise approaches along with your plant platforms. when you understand how to hyperlink your plant structures to generate finished and exact info, find out how to use SAP MII instruments to generate exact studies and dashboards for research and real-time tracking, resulting in a extra effective and potent store flooring.
Atlas of Fibre Fracture and Damage to Textiles, Second Edition
According to over 25 years of study on the college of Manchester Institute of technological know-how & know-how, Atlas of Fibre Fracture and harm to Textiles includes greater than 1,500 scanning electron micrographs and different photographs, supplying a distinct number of documentary details. The explanatory textual content provides fibre and polymer scientists an evidence of fracture mechanisms and descriptions technique to maximize cloth existence span, permitting cloth technologists and layout engineers to fabricate enhanced cloth items, and supporting forensic scientists to spot reason for failure.
Automatic Supervision in Manufacturing
Automation is a main goal within the improvement of recent and complex production construction. automated Supervision inManufacturing (ASM) addresses unavoidable disturbances taking place in the course of creation. Its software ends up in the unmanned functioning of producing platforms via complete and trustworthy supervision.
Extra info for Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals
Example text
9. Enck, R. , Betts, R. , Brown, M. , and Miller, G. (1979), Viral serology (hepatitis B virus, cytomegalovirus, Epstein-Barr virus) and abnormal liver function tests in transfused patients with hereditary hemorrhagic diseases, Transfusion 19: 32–38. 10. Curran, J. W. et al. (1984), Acquired immunodeficiency syndrome (AIDS) associated with transfusions, New Engl. J. Med . 310: 69–75. 11. Bray, B. L. (2003), Large-scale manufacture of peptide therapeutics by chemical synthesis, Nat. Rev . 2: 587–593.
2005), Upping the ante on antibodies, Nat. Biotechnol . 23: 1065–1072. 21. Itakura, K. et al. (1977), Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin, Science 198: 1056–1063. 22. Goeddel, D. V. et al. (1979), Expression in Escherichia coli of chemically synthesized genes for human insulin, Proc. Natl. Acad. Sci. USA 76: 106–110. 23. Goeddel, D. V. et al. (1979), Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone, Nature 281: 544–548.
The latest breakthrough in this field occurred in February 2009, when the FDA approved recombinant human antithrombin expressed in genetically engineered goats (ATryn by GTC Biotherapeutics) for the prevention of perioperative and peripartum thromboembolic events, in hereditary antithrombin deficient patients [16]. ) At the same time, there are a number of blood enzymes and factors that continue to be isolated from human serum, presumably due to the complexity of producing these proteins using recombinant technology combined with substantial improvements in the safety of the blood supply [67], such as albumin (by Octapharma in 2006) used to restore blood volume, alpha-1 proteinase inhibitor (Aralast by Baxter in 2002, Zemaira by Aventis Behring in 2003) for genetic emphysema, antihemophilic factor/von Willebrand factor complex (Alphanate, by Grifols Biologics in 2007 and Humate-P by CSL Behring in 2007), for hemophilia, C1 esterase inhibitor (Cinryze by Lev Pharmaceuticals in 2008) for use in hereditary angioedema attacks, immune globulin (by numerous 20 THE STRUCTURE OF BIOLOGICAL THERAPEUTICS companies) for immune deficient diseases, thrombin (Evithrom by Omrix Biopharmaceuticals in 2007) for an aid in hemostasis, and protein C (Ceprotin by Baxter in 2007) for venous thrombosis and purpura fulminans [16].
Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals by Feroz Jameel, Susan Hershenson
by Joseph
4.3